This is the hidden gem in the ann:
"Importantly, patients in the open label extension of the single ascending dose (SAD) study have already progressed to repeat dosing at the 75 mcg dose and there have been no Treatment Emergent- Serious Adverse Events (TE-SAE's) in patients who have now received three 75 mcg doses of VP-001."
Ann: RP11 SRC Approves Dose Escalation to Final Patient Cohort, page-3
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.23 |
Change
0.025(2.08%) |
Mkt cap ! $699.9M | |||
| Open | High | Low | Value | Volume |
| $1.20 | $1.23 | $1.20 | $393.8K | 327.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 15248 | $1.21 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.23 | 22001 | 2 |
View Market Depth
| Last trade - 10.20am 24/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |